https://www.benjaminyoungs.com/mergesort/biotech Biotech and pharma news from STAT, Endpoints, Fierce, BioPharma Dive and more, semantically deduplicated and ranked weekly en-us Mon, 12 Oct 2026 10:00:00 -0500 https://www.benjaminyoungs.com/mergesort/biotech/posts/2026-10-12/ https://www.benjaminyoungs.com/mergesort/biotech/posts/2026-10-12/ Mon, 12 Oct 2026 10:00:00 -0500 6 stories • FDA advisory panel recommends approval for multi-cancer early detection blood test • Broad 100% Tariff on Imported Pharmaceuticals Causes Industry Confusion • PhRMA Sues Trump Administration Over Medicare Drug Pricing Pilot Top Stories

FDA advisory panel recommends approval for multi-cancer early detection blood test

An FDA advisory panel recommended approval for a cancer blood test despite the test failing to meet its suboptimal surrogate endpoint in a randomized trial of 140,000 people. This decision paves the way for potential Medicare coverage under the recently passed Multi-Cancer Early Detection Screening Coverage Act.

product_launch · Covered by STAT Biotech

Broad 100% Tariff on Imported Pharmaceuticals Causes Industry Confusion

A 100% Section 232 tariff on imported pharmaceuticals and active ingredients has officially taken effect, sparking widespread confusion across the biopharma sector. While major drugmakers managed to secure delays via most-favored nation agreements, smaller biotech firms are left directly exposed to the heavy financial levies as they try to navigate complex exemption pathways.

policy · Covered by STAT Pharma

More Stories

PhRMA Sues Trump Administration Over Medicare Drug Pricing Pilot

The Pharmaceutical Research and Manufacturers of America has filed a lawsuit challenging the Trump administration's Medicare Part B 'GLOBE' pilot program, arguing it exceeds statutory authority by tying US drug prices to lower international rates. Separately, federal health officials are drafting plans to allow compounding pharmacies to temporarily sell certain restricted peptides.

policy · Covered by STAT Pharma

Dutch court rules Merck infringed on Halozyme's Keytruda patent

A Dutch court ruled that Merck infringed on a patent for the subcutaneous formulation of Keytruda, ordering a halt to its manufacturing and marketing in several European countries. The decision is part of a broader patent dispute with Halozyme Therapeutics, though the intravenous version of Keytruda remains unaffected.

policy · Covered by STAT Pharma

Admilparant trial results raise analyst questions in idiopathic pulmonary fibrosis

Only the lower of two tested doses of admilparant met the main objective in an idiopathic pulmonary fibrosis trial, creating uncertainty regarding the drug's future prospects.

research · Covered by BioPharma Dive

Plant biologist Nick Desnoyer develops 'Paintunia' using inducible genetic engineering

Researcher Nick Desnoyer is engineering petunias with inducible genes that activate specific pigmentation pathways when exposed to dexamethasone, creating a living canvas for botanical art.

research · Covered by Asimov Press

]]> https://www.benjaminyoungs.com/mergesort/biotech/posts/2026-10-05/ https://www.benjaminyoungs.com/mergesort/biotech/posts/2026-10-05/ Mon, 05 Oct 2026 10:00:00 -0500 6 stories • Eli Lilly's Zepbound Combination Therapy Shows Strong Weight Loss in Mid-Stage Study • Beam Therapeutics Sues Former Scientist Over Alleged IP Theft to Launch Chinese Competitor • Vaxcyte's Phase 3 pneumococcal vaccine hits primary endpoints Top Stories

Eli Lilly's Zepbound Combination Therapy Shows Strong Weight Loss in Mid-Stage Study

A mid-stage clinical trial of Eli Lilly's investigational combination therapy, which pairs its blockbuster weight-loss drug Zepbound with the amylin candidate eloralintide, achieved a 23.3% weight loss after 48 weeks. While the combination outperformed monotherapy treatments, high discontinuation rates due to tolerability issues have raised questions about its future development. This data comes amid a flurry of pipeline updates in the highly competitive obesity market, including new developments from Novo Nordisk, AbbVie, and Boehringer Ingelheim.

research · Covered by STAT Pharma · BioPharma Dive · STAT Pharma

Beam Therapeutics Sues Former Scientist Over Alleged IP Theft to Launch Chinese Competitor

Beam Therapeutics has filed a lawsuit against a former scientist, accusing them of stealing intellectual property and trade secrets to co-found YolTech Therapeutics, a Shanghai-based biotech startup. This legal action highlights escalating tensions and intellectual property security concerns between U.S. and Chinese biotechnology firms.

other · Covered by STAT Pharma · STAT Biotech

More Stories

Vaxcyte's Phase 3 pneumococcal vaccine hits primary endpoints

Vaxcyte announced that its experimental pneumococcal vaccine, VAX-31, successfully met primary endpoints in a Phase 3 clinical trial involving adults aged 50 and older. The 31-valent vaccine aims to compete directly with established offerings from Pfizer and Merck by protecting against a broader range of bacterial strains.

research · Covered by STAT Biotech

Sanofi and Regeneron expand partnership with $1 billion upfront deal for immunology antibodies

Sanofi and Regeneron have renewed their partnership to develop a new series of antibodies for immunological diseases, with Sanofi paying $1 billion upfront and up to $7 billion in potential milestones. Regeneron will lead R&D, Sanofi will handle commercialization, and profits will be split evenly.

partnership · Covered by STAT Pharma · BioPharma Dive

Merck and Moderna Report Positive Late-Stage Trial Results for mRNA Melanoma Vaccine

Adding an mRNA cancer vaccine to existing treatment successfully stopped the return and spread of melanoma in a late-stage clinical trial. These positive results boost hopes for the application of mRNA technology in treating other types of cancers.

research · Covered by STAT Pharma · STAT Pharma

UniQure's Huntington's Gene Therapy AMT-130 Slows Disease Progression by 44% at Four Years

Four-year clinical data for UniQure's experimental one-time gene therapy, AMT-130, showed a 44% slowing of Huntington's disease progression compared to an external control group. While the results demonstrate a sustained benefit, the treatment effect waned slightly between years three and four, and the difference was not statistically significant ahead of upcoming FDA reviews.

research · Covered by STAT Biotech

]]>